Kallesh D Jayappa
Overview
Explore the profile of Kallesh D Jayappa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
68
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pal I, Illendula A, Joyner A, Manavalan J, Deddens T, Sabzevari A, et al.
bioRxiv
. 2024 Jul;
PMID: 39071370
Histone deacetylase (HDAC) inhibitors are a widely recognized and valued treatment option for patients with relapsed or refractory peripheral T cell lymphomas (PTCL). Romidepsin is a relatively selective Class I...
2.
Jayappa K, Tran B, Gordon V, Morris C, Saha S, Farrington C, et al.
J Clin Invest
. 2023 May;
133(13).
PMID: 37166997
Targeted therapies such as venetoclax (VEN) (Bcl-2 inhibitor) have revolutionized the treatment of chronic lymphocytic leukemia (CLL). We previously reported that persister CLL cells in treated patients overexpress multiple antiapoptotic...
3.
Jayappa K, Gordon V, Morris C, Wilson B, Shetty B, Cios K, et al.
Blood Adv
. 2021 Aug;
5(17):3497-3510.
PMID: 34432864
The Bcl-2 inhibitor venetoclax has yielded exceptional clinical responses in chronic lymphocytic leukemia (CLL). However, de novo resistance can result in failure to achieve negative minimal residual disease and predicts...
4.
Jayappa K, Portell C, Gordon V, Capaldo B, Bekiranov S, Axelrod M, et al.
Blood Adv
. 2017 Oct;
1(14):933-946.
PMID: 29034364
resistance and rapid recurrence often characterize responses of B-cell malignancies to ibrutinib (IBR), indicating a need to develop drug combinations that block compensatory survival signaling and give deeper, more durable...
5.
Jayappa K, Kovi R, Chatterjee S
Biomed Res Int
. 2016 Aug;
2016:4650498.
PMID: 27478830
No abstract available.